Denise L Jacobson1, Jane C Lindsey1, Catherine Gordon2, Rohan Hazra3, Hans Spiegel4, Flavia Ferreira5, Fabiana R Amaral6, Jesica Pagano-Therrien7, Aditya Gaur8, Kathy George9, Jane Benson10, George K Siberry11. 1. Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. 2. Division of Adolescent/Young Adult Medicine, Boston Children's Hospital, Boston, Massachusetts, USA. 3. Maternal and Pediatric Infectious Diseases Branch, Division of Extramural Research, Department of Health and Human Services, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA. 4. Kelly Government Solutions, contractor to National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA. 5. Department of Pediatrics, Federal University of Minas Gerais, Belo Horizonte, Brazil. 6. Department of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil. 7. Graduate School of Nursing, University of Massachusetts, Worcester, Massachusetts, USA. 8. St Jude Children's Research Hospital, Memphis, Tennessee, USA. 9. Family Health International 360, Durham, North Carolina, USA. 10. Department of Radiology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. 11. Office of HIV/AIDS, US Agency for International Development, Arlington, Virginia, USA; for the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1076 Study Team.
Abstract
BACKGROUND:Children and adolescents with perinatal human immunodeficiency virus (HIV) infection and with low bone mineral density (BMD) may be at higher risk of osteoporosis and fractures in later life than their uninfected peers. Bisphosphonate therapy has been shown to reduce fractures in adults with osteoporosis, but has not been formally studied in youths living with HIV. METHODS:Fifty-two children and adolescents (aged 11-24 years) perinatally infected with HIV with low lumbar spine (LS) BMD (Z score < -1.5) were randomized to receive once-weekly alendronate or placebo in a double-blind cross-over study designed to assess the safety and efficacy of 48 and 96 weeks of alendronate in the United States and Brazil. All participants received daily calcium carbonate and vitamin D supplementation and were asked to engage in regular weight-bearing exercise. Safety and efficacy are summarized for the initial 48 weeks of the trial. RESULTS: Grade 3 or higher abnormal laboratory values, signs, or symptoms developed in 5 of 32 (16%) participants on alendronate and 2 of 18 (11%) on placebo (P > .99). No cases of jaw osteonecrosis, atrial fibrillation, or nonhealing fractures were reported. Mean increases (95% confidence interval) in LS BMD over 48 weeks were significantly larger on alendronate (20% [14%-25%]) than placebo (7% [5%-9%]) (P < .001). Similar improvements were seen for whole body BMD. CONCLUSIONS: In this small study in children and adolescents perinatally infected with HIV with low LS BMD, 48 weeks ofalendronate was well-tolerated, showed no safety concerns, and significantly improved LS and whole body BMD compared to participants on vitamin D/calcium supplementation and exercise alone. CLINICAL TRIALS REGISTRATION: NCT00921557.
RCT Entities:
BACKGROUND:Children and adolescents with perinatal human immunodeficiency virus (HIV) infection and with low bone mineral density (BMD) may be at higher risk of osteoporosis and fractures in later life than their uninfected peers. Bisphosphonate therapy has been shown to reduce fractures in adults with osteoporosis, but has not been formally studied in youths living with HIV. METHODS: Fifty-two children and adolescents (aged 11-24 years) perinatally infected with HIV with low lumbar spine (LS) BMD (Z score < -1.5) were randomized to receive once-weekly alendronate or placebo in a double-blind cross-over study designed to assess the safety and efficacy of 48 and 96 weeks of alendronate in the United States and Brazil. All participants received daily calcium carbonate and vitamin D supplementation and were asked to engage in regular weight-bearing exercise. Safety and efficacy are summarized for the initial 48 weeks of the trial. RESULTS: Grade 3 or higher abnormal laboratory values, signs, or symptoms developed in 5 of 32 (16%) participants on alendronate and 2 of 18 (11%) on placebo (P > .99). No cases of jaw osteonecrosis, atrial fibrillation, or nonhealing fractures were reported. Mean increases (95% confidence interval) in LS BMD over 48 weeks were significantly larger on alendronate (20% [14%-25%]) than placebo (7% [5%-9%]) (P < .001). Similar improvements were seen for whole body BMD. CONCLUSIONS: In this small study in children and adolescents perinatally infected with HIV with low LS BMD, 48 weeks of alendronate was well-tolerated, showed no safety concerns, and significantly improved LS and whole body BMD compared to participants on vitamin D/calcium supplementation and exercise alone. CLINICAL TRIALS REGISTRATION: NCT00921557.
Authors: Gillian A Hawker; Rowena Ridout; Vivien A Harris; Cheryl C Chase; Lynda J Fielding; W Douglas Biggar Journal: Arch Phys Med Rehabil Date: 2005-02 Impact factor: 3.966
Authors: Linda A DiMeglio; JiaJia Wang; George K Siberry; Tracie L Miller; Mitchell E Geffner; Rohan Hazra; William Borkowsky; Janet S Chen; Laurie Dooley; Kunjal Patel; Russell B van Dyke; Roger A Fielding; Yared Gurmu; Denise L Jacobson Journal: AIDS Date: 2013-01-14 Impact factor: 4.177
Authors: Peter L Havens; Charles B Stephensen; Marta D Van Loan; Gertrud U Schuster; Leslie R Woodhouse; Patricia M Flynn; Catherine M Gordon; Cynthia G Pan; Brandy Rutledge; D Robert Harris; Georgine Price; Alyne Baker; William A Meyer; Craig M Wilson; Rohan Hazra; Bill G Kapogiannis; Kathleen Mulligan Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079
Authors: Alison M Boyce; Marilyn H Kelly; Beth A Brillante; Harvey Kushner; Shlomo Wientroub; Mara Riminucci; Paolo Bianco; Pamela G Robey; Michael T Collins Journal: J Clin Endocrinol Metab Date: 2014-07-17 Impact factor: 5.958
Authors: Jane C Lindsey; Denise L Jacobson; Hans M Spiegel; Catherine M Gordon; Rohan Hazra; George K Siberry Journal: Clin Infect Dis Date: 2021-03-15 Impact factor: 9.079